Study of some physiological parameters in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DOI:
https://doi.org/10.36320/ajb/v8.i3.9305Keywords:
Autosomal Dominant Polycystic Kidney Disease, physiological parameters.Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common Mendelian disorder of the kidney and affects all racial groups worldwide. It is characterized by focal development of renal and extrarenal cysts in an age-dependent manner. This study tested some physiological parameters in two groups of patients with ADPKD, the first group included patients with kidney failure and the second group included patients without renal failure as well as the control group. The study showed an increase in urea and uric acid in the serum of the patients without renal failure compared with the control levels and were higher in the patients with renal failure compared with the patients without renal failure, which amounted to 115.8 mg / dL and 10,278 mg / dL and 22.45 mg / dL and 7,264 mg / dL and 11.03 mg / dL and 3,264 mg /dL respectively. Creatinine serum level was higher in the patients with renal failure compared with the patients without renal failure and control, reaching 3.5 mg / dL , compared with 1,026 mg / dL and 0986 mg / dL , respectively. Potassium ion level was higher in patients without renal failure than in control reaching 4,179 mmol / L and 2.34 mmol / L, respectively, while the level was higher in patients with renal failure than in patients without renal failure where it reached 7.09 mmol / l. Sodium ion levels were low in the patients with renal failure and the patients without renal failure than in the control group, reaching 87.06 mmol / l and 129 843 mmol / l and 147.25 mmol / L, respectively. The level of sodium ion was lower in the patients with renal failure than in the patients without renal failure. Results of the study showed normal levels in serum albumin and liver enzymes, AST and ALT.
Downloads
References
Ratnam, S. and Nauli, S.M. (2010). Hypertension in Autosomal Dominant Polycystic Kidney Disease: A Clinical and Basic Science Perspective. Int. J Nephrol. Urol.,2(2):294-308.
Masoumi,A.;Reed-Gitomer,B.;Kelleher,C.;Bekheirnia,M.R. and Schrier, R.W. (2008). Developments in the management of autosomal dominant polycystic kidney disease. Therapeutics and Clinical Risk Management,4(2):393-407. DOI: https://doi.org/10.2147/TCRM.S1617
Pei,Y.Obaji,J.Dupuis,A.Paterson,AD.Magistroni,R.Dicks,E.Parfrey,P.Cramer,B. Coto,E.Torra,R.San Millan,JL. Robert Gibson,R. Breuning,M. Peters,D and Ravine,D. (2009). Unified criteria for ultrasonographic diagnosis of ADPKD. J. Am. Soc. Nephrol.20:205–212. DOI: https://doi.org/10.1681/ASN.2008050507
Torres, V.E. and Harris, P. C. (2009). Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int.,76:149-168. DOI: https://doi.org/10.1038/ki.2009.128
Harris, P.C. and Rossetti S. (2010). Molecular diagnostics for autosomal dominant polycystic kidney disease. Nat Rev Nephrol., 6(4):197-206. DOI: https://doi.org/10.1038/nrneph.2010.18
Igarashi, P. and Somlo S.(2002) Genetics and pathogenesis of polycystic kidney disease. J Am Soc.Nephrol.13:2384-98. DOI: https://doi.org/10.1097/01.ASN.0000028643.17901.42
Nauli, S. M., Alenghat F.J., Luo Y., Williams E., Vassilev P., Li X., EliaA.E., Lu W., Brown E.M., Quinn S.J., Ingber D.E., and Zhou J.(2003). Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet. 33:129-137. DOI: https://doi.org/10.1038/ng1076
Ravine, D. Gibson R.N, Walker R.G, Sheffield L.J, Kincaid-Smith P., Danks D.M.( 1994) Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet.343:824-7. DOI: https://doi.org/10.1016/S0140-6736(94)92026-5
DeRossi,S.S. and Cohen,S.G. (2003). Renal Disease. Chapter 15 from: Greenberg,M.S. and Glick,M. (eds). Burket's oral medicine. Diagnosis and treatment 10th Edn. Inc. Hamilton.
Chapman,A.B.; Bost,J.E.; Torres,V.E.; Guay-Woodford,L. and Others. (2012). Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol .,7: 479–486. DOI: https://doi.org/10.2215/CJN.09500911
Walker,R. and Edwards,C.(2003). Clinical pharmacy and therapeutics. 3ed Ed. Elsevier Science. 937P.
Wang,X.; Wu,Y.; Ward,C.J.; Harris,P.C. and Torres,V.E.(2008). Vasopressin Directly Regulates Cyst Growth in Polycystic Kidney Disease. J Am Soc Nephrol.,19: 102-108. DOI: https://doi.org/10.1681/ASN.2007060688
Bankir,L. and Bichet,D.G. (2012). An early urea-selective urine-concentrating defect in ADPKD. Nat. Rev. Nephrol.,8: 437-439. DOI: https://doi.org/10.1038/nrneph.2012.139
Hopp,K.;Ward,C.J.;Hommerding,C.J.;Nasr,S.H.;Tuan,H.;Gainullin,V. G. ;Rossetti,S.; Torres,V.E. and Harris,P.C.(2012). Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest.,122(11):4257-4273. DOI: https://doi.org/10.1172/JCI64313
Hsu,S.; Pai,M.; Peng,Y.; Chiang,C.; Ho,T. and Hung,K.(2004). Serum uric acid levels show a ‘J-shaped’ association with all-cause mortality in hemodialysis patients. Nephrol Dial Transplant.,19: 457-462. DOI: https://doi.org/10.1093/ndt/gfg563
Feig,D.I.; Kang,D. and Johnson,R.J.(2009).Uric Acid and Cardiovascular Risk. N Engl J Med.,359:1811-21. DOI: https://doi.org/10.1056/NEJMra0800885
Helal,I.; Lassoued,F.; Maiz,H.B. and Kheder, A. (2013a). Clinical Presentation and Outcomes of Autosomal Dominant Polycystic Kidney Disease in the Elderly. Am J Med Sci Med.,1(1):18-20. DOI: https://doi.org/10.12691/ajmsm-1-1-3
Torres,VE. Harris,PC. And Pirson,Y.(2007). Autosomal dominant polycystic kidney disease. Lancet,369: 1287–1301. DOI: https://doi.org/10.1016/S0140-6736(07)60601-1
Helal,I.;McFann,K.;Reed,B.;Yan,X.;Schrier,R.W. and Fick-Brosnahan, G.M. (2013b). Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 28: 380-385. DOI: https://doi.org/10.1093/ndt/gfs417
Meijer,E;Rook,M.Tent,H.;Navis,G.;van der Jagt,E.J.;de Jong,P.E. and Gansevoort,R.T.(2010). Early Renal Abnormalities in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol 5: 1091-1098. DOI: https://doi.org/10.2215/CJN.00360110
Azurmendi,P.J.; Fraga,A.R.; Galan,F.M.;Kotliar2,C.;Arrizurieta,E.E.; Valdez,M.G.; Forcada,P.J.;Stefan,J.S. and Martin,R.S.(2009). Early renal and vascular changes in ADPKD patients with low-grade albumin excretion and normal renal function. Nephrol Dial Transplant., 24: 2458-2463. DOI: https://doi.org/10.1093/ndt/gfp136
Yoo,D.J.; Agodoa,L.; Yuan,M.; Abbott,K.C. and Nee,R. (2014). Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease. BMC Nephrology,15:39. DOI: https://doi.org/10.1186/1471-2369-15-39
An, J.N.; Lee,J.P.; Jeon,H.J.; Kim,D.H.; Oh,Y.K.; Kim,Y.S. and Lim, C.S. (2012). Severe hyperkalemia requiring hospitalization: predictors of mortality. Critical Care, 16(R225):1-14. DOI: https://doi.org/10.1186/cc11872
Veeramuthumari,P. and Isabel,W. (2013). Clinical study on Autosomal Dominant Polycystic Kidney Disease among South Indians. Int J Clin Med.,4:200-204. DOI: https://doi.org/10.4236/ijcm.2013.44035
Al-Ghamdi,G.; Hemmelgarn,H.; Klarenbach,S.; Manns,B.;Wiebe,N. and Tonelli.M. (2010). Dialysate potassium and risk of death in chronic hemodialysis patients. J Nephrol., 23 (1):33-40.
Mushiyakh,Y.; Dangaria,H.; Qavi,S.; Ali,N.; Pannone,J. and Tompkins,D. (2011). Treatment and pathogenesis of acute hyperkalemia. J Community Hospital Internal Medicine Perspectives,1(4): 7372-77. DOI: https://doi.org/10.3402/jchimp.v1i4.7372
Espinel,E.; Joven,J.; Gil,I.; Sune.P.; Renedo,B.; Fort,J. and Seron,D. (2013). Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Research Notes, 6(306):1-9. DOI: https://doi.org/10.1186/1756-0500-6-306
Kovesdy,C.P.; Lott,E.H.;Lu,J.L.; Malakauskas,S.; Ma,J.Z.; Molnar, M.Z. and Kalantar-Zadeh,K. (2012). Hyponatremia, Hypernatremia and Mortality in Patients with Chronic Kidney Disease with and without Congestive Heart Failure. Circulation,125(5): 677–684. DOI: https://doi.org/10.1161/CIRCULATIONAHA.111.065391
Kim,S. (2011). Hyponatremia and Hypokalemia in Peritoneal Dialysis Patients: In: Krediet,R. (Ed.). Progress in Peritoneal Dialysis.InTech, PP145-156. DOI: https://doi.org/10.5772/21849
Shannon,G. (2011). Severe hyponatraemia-recognition and management. Aust Prescr.,34: 42-45. DOI: https://doi.org/10.18773/austprescr.2011.027
Oreopoulos,D.G.; Bell,T.K. and McGeown,M.G. (1971). Liver function and liver scan in patients with polycystic kidney disease. Br J Urol.,43(3):273-276. DOI: https://doi.org/10.1111/j.1464-410X.1971.tb12039.x
Torres,V.E.; Rastogi,S.; King,B.F.; Stanson,A.W.; Gross Jr,J.B. and Nagorney,D.M. (1994). Hepatic Venous Oufflow Obstruction in Autosomal Dominant Polycystic Kidney Disease. Am J Soc Nephrol., 5:1186-1192. DOI: https://doi.org/10.1681/ASN.V551186
Chauveau, D., Fakhouri F.,and Grunfeld J.P. (2000). Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. J Am Soc Nephrol.,11:1767-75. DOI: https://doi.org/10.1681/ASN.V1191767
Tasci,I.; Bulucu,F.; Mas,M.R. and Verim,S. (2005). Polycystic kidney disease with highly elevated γ-glutamate transpeptidase. Eur J Gen Med., 2(1):39-40. DOI: https://doi.org/10.29333/ejgm/82265
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Rafie S. Al-Khafaji, Haider K. Zaidan, Ali H. Al-Saadi
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
